According to Arch Biopartners, the US Patent and Trademark Office has issued US Patent 9,925,206, “Compositions and Methods for Treating Bacterial Infection,” which covers the composition of AB569 sodium nitrite/ethylenediaminetetraacetic acid (EDTA), to the University of Cincinnati.
Arch acquired an exclusive license for AB569 from the university in March 2016 and is developing an inhaled formulation of the drug for the treatment of P. aeruginosa lung infections in cystic fibrosis and COPD patients. Both the US and Europe have granted orphan drug designation for AB569 for the treatment of cystic fibrosis patients, the company said.
In April 2017, Arch announced that it was initiating a Phase 1 trial of AB569 that would be conducted by the Cincinnati Veterans Affairs Medical Center, and the company says that that trial is underway.
Arch CEO Richard Muruve commented, “This patent issuance, which protects the composition of AB569, gives Arch a stronger commercial position to pursue treating not just CF patients, but also the millions of other patients that have chronic antibiotic resistant lung infections including those with COPD. It also opens the door for Arch to develop treatments for many other indications where antibiotic resistance is a problem, such as urinary tract infections and wound care.”
Read the Arch Biopartners press release.
